Constitutively Active Androgen Receptor Variants Upregulate Expression of Mesenchymal Markers in Prostate Cancer Cells

Félicie Cottard¹, Irène Asmane¹,², Eva Erdmann¹, Jean-Pierre Bergerat¹,², Jean-Emmanuel Kurtz¹,², Jocelyn Céraline¹,²*

¹INSERM U1113, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France, ²CHRU Strasbourg, Hematology and Oncology Unit, Strasbourg, France

Abstract

Androgen receptor (AR) signaling pathway remains the foremost target of novel therapeutics for castration-resistant prostate cancer (CRPC). However, the expression of constitutively active AR variants lacking the carboxy-terminal region in CRPC may lead to therapy inefficacy. These AR variants are supposed to support PCa cell growth in an androgen-depleted environment, but their mode of action remains unresolved. Moreover, recent studies indicate that constitutively active AR variants are expressed in primary prostate tumors and may contribute to tumor progression. The aim of this study was to investigate the impact of constitutively active AR variants on the expression of tumor progression markers. N-cadherin expression was analyzed in LNCaP cells overexpressing the wild type AR or a constitutively active AR variant by qRT-PCR, Western blot and immunofluorescence. We showed here for the first time that N-cadherin expression was increased in the presence of constitutively active AR variants. These results were confirmed in C4-2B cells overexpressing these AR variants. Although N-cadherin expression is often associated with a downregulation of E-cadherin, this phenomenon was not observed in our model. Nevertheless, in addition to the increased expression of N-cadherin, an upregulation of other mesenchymal markers expression such as VIMENTIN, SNAIL and ZEB1 was observed in the presence of constitutively active variants. In conclusion, our findings highlight novel consequences of constitutively active AR variants on the regulation of mesenchymal markers in prostate cancer.

Introduction

Prostate cancer (PCa) is the most common cancer in men over 50 years of age and the second cause of male mortality due to cancer in Europe. Androgens signaling plays a key role in PCa cells proliferation or survival [1], and androgen withdrawal remains the main treatment for local recurrence and androgen-dependent metastatic PCAs. However, the benefit of this therapy is transient and all tumors ultimately recur as castration-resistant PCAs (CRPC).

Genetic and splicing events affecting the androgen receptor (AR) gene have been linked to CRPC. Constitutively active AR variants, lacking the carboxy-terminal region that encompasses the ligand binding domain and the activation function 2, might contribute to the progression of PCa into castration resistance. These constitutively active AR variants result from premature stop codons due to nonsense mutations as reported for the ARQ640X [2,3,4,5] or from alternative splicing with the retention of a cryptic exonic sequence as described for AR-V7 [4,6,7,8,9,10].

The role of constitutively active AR variants in CRPC has been shown in many studies [7,8,11,12]. The expression of these truncated AR variants is increased by a 20-fold in CRPC compared with localized PCa [9], and is correlated with the capacity of PCa cells to grow in vitro and in vivo in the absence of androgen [7]. However, the exact molecular mechanisms leading to their activation and their mode of action in PCa and CRPC remain unclear.

Recent studies suggest that constitutively active AR variants could play a role in tumor progression. Indeed, although these constitutively active AR variants are already expressed in primary prostate tumors, their expression is all the more expressed in bone metastasis [8]. Furthermore, their expression is associated with an increase of NFAT (Nuclear factor of activated T-cell) and AP-1 (Activator Protein-1) activity, two transcription factors involved in cell proliferation, migration and survival [13].

N-cadherin, which belongs to cadherin superfamily, is located at adherens junctions in nervous, endothelial or mesenchymal cells and is involved in tumor progression [14,15]. Indeed, N-cadherin expression is increased in most cancers and promotes tumor cells migration, invasion and survival [14]. Increased N-cadherin expression is also associated with epithelial-mesenchymal transition (EMT), a phenomenon characterized by a decrease of epithelial markers such as E-cadherin and an increase of...
mesenchymal markers such as Vimentin or N-cadherin [16,17,18,19]. These molecular and cellular modifications play an important role in tumor cells dissemination at secondary sites [20,21].

More recently, studies have shown that castration-resistant PCa is associated with an upregulation of N-cadherin expression in cellular models as well as PCa xenografts and clinical samples of CRPC [22,23,24]. Moreover, monoclonal antibodies against N-cadherin have been shown to delay the emergence of castration resistance and to reduce the growth of CRPC xenografts [23]. Taken together, these data show that there is a correlation between N-cadherin expression and resistance to castration. Nevertheless, molecular mechanisms whereby N-cadherin expression is increased in CRPC remain unknown.

The aim of this work was to show a possible link between the presence of constitutively active AR variants and the expression of tumor progression markers. More particularly, we focused on the impact of constitutively active AR variants on the expression of N-cadherin and other mesenchymal markers. In the present study, we have shown that N-CADHERIN as well as VIMENTIN, SNAIL and ZEB1 are upregulated in the presence of constitutively active AR variants in PCa.

Materials and Methods

Cell culture

The human prostate carcinoma LNCaP cell line, clone FGC and the 22Rv1 cell line (ECACC, Salisbury, United Kingdom) was maintained in RPMI-1640 medium complete containing 10% fetal calf serum (FCS), 10 mM HEPES, 2 mM L-glutamine, 100 U/mL penicillin, 100 µg/mL streptomycin (Sigma-Aldrich, France) and 1mM sodium pyruvate (Invitrogen, Fisher Scientific, France).

C4-2B cell line (ViroMed Laboratories, Minnetonka, MN, USA) was maintained in DMEM medium supplemented with 20% Ham’s F12, 10% FCS, 100 U/mL penicillin, 100 µg/mL streptomycin, 5 µg/mL insulin, 13.65 pg/mL triiodo-thyronine, 4.4 µg/mL apotransferrin human, 0.244 µg/mL d-biotin and 12.5 µg/mL adenosine (Sigma-Aldrich, France).

Plasmids and transfection

For immunofluorescence experiments, the wild type androgen receptor (AR) (AR-WT) and the constitutively active AR Q640X and AR Q670X [25] variants were linked to EGFP as previously described [2,3]. For gene expression analysis and Western-blot, pE-AR-WT, pE-ARQ640X and pE-AR-V7 plasmids were constructed by inserting the corresponding AR cDNA between the NheI and BamHI sites in pEGFP-C3.

For transfections, the JetPEI transfection reagent (Polyplus Transfection, Ozyme, France) was used according to the manufacturer’s protocol. LNCaP cells were seeded in 10 cm dishes at 1 x 10^6 cells/dish or in 6-wells plate at 2 x 10^5/well. Three days later, the medium was changed and cells were transfected with 10 µg of the indicated plasmid using 20 µL of JetPEI transfection reagent for 10 cm dishes or with 3 µg of plasmid using 6 µL of JetPEI for 6-wells plate. Medium was changed 48 h after and cells were incubated up to 9 days according to the experiments. The medium was changed every two days and for incubations beyond 4 post-transfection days, cells were incubated in the presence of 400 µg/mL gentamicin (Invitrogen, France).

Impact of androgens on N-cadherin expression

LNCaP cells were seeded in 6-wells plate in complete medium and transfected as previously described. Twenty four hours later, medium was changed to phenol red free RPMI-1640 supplemented with 3% dextran-coated charcoal-stripped FCS (DCC-FCS) and with the indicated concentration of dihydrotestosterone (DHT) (Sigma-Aldrich, France) or vehicle (ethanol).

For experiment with MDV3100, transfected LNCaP cells were incubated in RPMI-1640 supplemented with 5% DCC-FCS containing the indicated DHT dose and 100 nM MDV3100 (Enzalutamidine, Selleck Chemicals, Euromex, France) or vehicle (dimethyl sulfoxide, DMSO). To confirm the effects of androgens on N-cadherin expression, 22Rv1 cells were grown in RPMI-1640 with 100 nM or 1 µM MDV3100, or DMSO.

Cell Sorting

LNCaP cells were seeded in 10cm dishes at 1 x 10^6 cells/dish and were transfected with pEGFP-AR-WT or pEGFP-ARQ640X. Four days after transfection, cells were trypsinized and sorted thanks to the green fluorescence (EGFP) with a BD FACSaria-II cell sorter (BD Biosciences, Le Pont de Claix, France). Total RNA was extracted from EGFP negative (non-transfected) and EGFP positive (transfected) cells and was used to analyze gene expression by qRT-PCR.

Quantitative real-time PCR

Total cellular RNA was extracted from cell lines using NucleoSpin RNA II assay (Macherey-Nagel, France) according to the manufacturer’s procedure. RNA concentrations and purity were quantified measuring the absorbance at 260 nm and 280 nm (GeneQuant pro, GE Healthcare, France). The reverse transcription was performed from 400 ng or 1 µg RNA using RT Omniscript assay (Qiagen, Courtaboeuf, France). RNA were diluted into 13 µL and denatured at 65°C during 5 minutes. A 7 µL reaction mix containing 1xRT template, 0.5 mM of each dNTP, 1 µM oligo dT, 10U RNase inhibitor and 4U Omniscript Reverse Transcriptase was added and the reaction was incubated 1 h at 37°C. The reaction was stopped by heating to 93°C for 5 minutes. N-CADHERIN, E-CADHERIN, VIMENTIN, SNAIL, TWIST1, and ZEB1 mRNA levels were quantified using real-time PCR with LightCycler® 480 (Roche Applied Science, Meylan, France). For PCR reactions, 5 µL LightCycler® 480 SYBR Green I Master (Roche, Molecular Diagnostics, Mannheim, Germany) and 1 µL specific primers (Table 1) (Qiagen, QuantiTect Primers, Courtaboeuf, France) were mixed with 4 µL of 1:5 DNA dilution. Results were normalized using housekeeping gene β-ACTIN or PBGD (Porphobilinogen deaminase) (Qiagen, QuantiTect Primer). Amplification specificity was verified by analyzing melting curve and by electrophoresis migration. All experiments were realized in triplicate and repeated 3 times. Relative quantification was used to determine fold change in expression level by the ΔΔCt method. Each value is expressed as the mean ΔΔCt ± SEM. Results were analyzed with Student t test and p-value <0.05 was considered significant.

Western Blot

Blots were loaded in buffer containing 10 mM Tris-HCl pH7, 140 mM NaCl, 3 mM MgCl2, 0.5% Igepal, 5 mM DTT, 1x phosphatase inhibitor, and 1x protease inhibitor. Protein concentration for each sample was quantified using BCA Protein Assay (Pierce Biotechnology, Inc., Rockford, IL, USA) according to the manufacturer’s procedure. A quantity of 15 µg to 100 µg of total proteins was loaded on 7.5% SDS-PAGE. After migration and transfer to nitrocellulose membrane, membranes were saturated with PBS/0.1%Tween/2%ECL and incubated at 4°C overnight with 0.1 µg/mL mouse monoclonal anti N-cadherin (catalog no. 610920, BD Biosciences, France) or 1 µg/mL mouse...
remained unchanged in LNCaP cells overexpressing AR-WT.

**Immunofluorescence Staining**

Lab-Tek II chamber slides (2 wells) were coated with LNCaP medium for two hours and 1×10⁵ LNCaP cells/well were seeded. LNCaP cells were transfected with 2 μg of pEGFP-WT, pEGFP-ARQ640X or pEGFP-ARQ670X 3 days later and incubated for 4 days. LNCaP cells were rinsed in PBS and fixed with 2% paraformaldehyde. Cells were blocked and permeabilized by 0.1% Triton/1% Bovine Serum Albumin (BSA)/PBS for 30 min at room temperature. Cultures were incubated with 2.5 μg/mL anti-N-cadherin mouse monoclonal antibody (catalog no. 610920, BD Biosciences, France) or isotypic antibody (Sigma-Aldrich, Saint-Quentin Fallavier, France) at 4°C overnight. After washing in PBS, LNCaP cells were incubated with 2 μg/mL Alexa Fluor 568-conjugated goat anti mouse (Invitrogen, Fisher Scientific, France) for 1 h and nuclei were stained with 0.1 μg/mL DAPI solution for 20 min at 30°C. Images were captured with the Leica LAS AF6000 fluorescence microscope using LAS AF software (Leica).

**Results**

**Constitutively active androgen receptor variants upregulate N-cadherin expression in prostate cancer cells**

Constitutively active AR variants have been associated with CRPC. Moreover, some studies showed that CRPC is also associated with an upregulation of N-cadherin expression [22,23]. We investigated whether constitutively active AR variants upregulate N-cadherin expression in PCa cells. N-CADHERIN mRNA level was determined by qRT-PCR in LNCaP cells overexpressing the constitutively active AR Q640X or AR-V7, or the AR-WT as control (Figure 1). N-CADHERIN expression remained unchanged in LNCaP cells overexpressing AR-WT compared with controls. Interestingly, N-CADHERIN expression was increased by a 8,000-fold in the presence of ARQ640X and AR-V7 (Figure 1A-B). These data were confirmed in C4-2B cells (Figure S1) and at the protein level in LNCaP cells (Figure 1C). In addition, a time course experiment revealed that N-cadherin protein levels were consistently increased from day-3 after LNCaP cells transfection with ARQ640X (Figure 1D).

To confirm these data from transient transfection, a cell-sorting analysis was performed after LNCaP transfection to demonstrate that N-cadherin expression was restricted to cells expressing a constitutively active AR. N-CADHERIN expression was analyzed in EGFP negative (non-transfected cells) or EGFP positive (transfected cells) fractions by qRT-PCR. Consistent with above results, N-CADHERIN expression was undetected in both EGFP-negative and positive fractions following LNCaP transfection with pEGFP-ARWT. However, upon transfection with pEGFP-ARQ640X, N-CADHERIN expression was increased in EGFP positive cells overexpressing the constitutively active AR, but not in the EGFP negative fraction (Figures 2A-B). These results were further confirmed by immunofluorescence analysis showing an N-cadherin labeling exclusively in EGFP positive cells expressing a constitutively active AR variant (Figure 2C).

Taken together, these data strongly suggest that constitutively active AR variants upregulate N-cadherin expression in PCa cells.

**Androgens negatively regulate N-cadherin expression induced by constitutively active androgen receptor variants**

A recent study reported that constitutively active AR variants might require a full-length AR (AR-FL) to activate endogenous target genes. To explore the effect of the endogenous AR-FL present in LNCaP cells on the ability of constitutively active AR variants to induce N-cadherin expression, LNCaP cells overexpressing AR-WT or a constitutively androgen variant were incubated in the presence of 100 nM DHT or vehicle, and N-cadherin expression was analyzed by qRT-PCR. In accordance with our previous results, no N-cadherin expression was observed in cells overexpressing AR-WT. Interestingly, a 1.4-fold decrease in N-cadherin expression level was observed when cells overexpressing AR Q640X or AR-V7 were cultured in the presence of 100 nM DHT compared to vehicle (Figure 3A). In addition, this androgen-mediated N-cadherin repression was dose-dependent (Figure 3B). These results suggest that constitutively active androgen receptor variants do not require AR-FL to up-regulate N-cadherin expression. However, DHT-activated AR-FL seems to antagonize effects of constitutively active androgen receptor variants on N-cadherin expression (Figure 3C). To verify this hypothesis, the novel anti-androgen MDV3100 was used to inhibit DHT-activated AR-FL in transfected LNCaP cells. As expected, a further significant increase of N-cadherin expression was observed in LNCaP cells overexpressing AR variants in the presence of

**Table 1. List of primers used in qRT-PCR experiments.**

| Genbank          | QuantiTect reference   | Hybridization temperature (°C) | Amplicon length (bp) | Amplified exons |
|------------------|------------------------|-------------------------------|----------------------|-----------------|
| β-ACTIN (ACTB)   | QT01680476             | 55/60                         | 104                  | NA              |
| E-CADHERIN (CDH1) | QT00080143             | 55                            | 84                   | 5/6             |
| N-CADHERIN (CDH2) | QT00063196             | 60                            | 102                  | 14/15           |
| PBGD (HMBS)      | QT00014462             | 55                            | 107                  | 7/8/9           |
| TWIST1           | QT0001956              | 55                            | 127                  | 1/2             |
| SNAIL (SNAI1)    | QT00010010             | 60                            | 131                  | 2/3             |
| VIMENTIN         | QT00095795             | 60                            | 94                   | 2/3             |
| ZEB1             | QT0188446              | 58                            | 105                  | 2/3/4           |

doi:10.1371/journal.pone.0063466.t001
100 nM MDV3100 (Figure 3D). These results were also confirmed in castration-resistant 22Rv1 cells, known to express both AR-FL and constitutively active AR variants. A 2-fold increase in N-cadherin mRNA level was observed when 22Rv1 cells were cultured for 4 days in the presence 100 nM and 1 μM of the anti-androgen MDV3100 (Figure S2).

All together, these data suggest that DHT-activated AR-FL could compete with constitutively active androgen receptor for regulating N-cadherin expression.

Constitutively active androgen receptor variants are associated with the expression of mesenchymal markers

It is widely known that in tumor cells, the expression of mesenchymal markers is associated with a down-regulation of epithelial markers. We hypothesized that the upregulation of N-cadherin expression observed in the presence of constitutively active AR variants is accompanied by a decreased expression of E-cadherin. To test this hypothesis, we analyzed E-cadherin expression in LNCaP transfected with ARQ640X or AR-V7 when compared with controls respectively (Figure 4B). Although Twist1 is known to induce N-CADHERIN expression in PCa, no significant difference in the mRNA levels of TWIST1 was observed (Figure 4C). However, constitutively active AR variants led to a statistically significant increase of SNAIL and ZEB1 mRNA levels (Figure 4D, E). ZEB1 upregulation was also confirmed at the protein level (Figure 4F).

**Discussion**

The AR signaling is very important for proliferation and survival of prostate cancer cells. The AR pathway remains activated during the progression of PCa towards a castration-resistant state.
resistant disease and the emergence of constitutively active AR variants lacking the ligand-binding domain is now considered as a major event in CRPC. In spite of some studies suggest that constitutively active AR variants have an impact on tumor progression, their function remains so far unresolved.

Figure 2. N-cadherin upregulation was restricted to LNCaP cells expressing constitutively active androgen receptor variants. LNCaP cells were transiently transfected with pEGFP-ARWT or pEGFP-ARQ640X plasmid and were sorted 4 days after. A). N-CADHERIN expression was analyzed by qRT-PCR in EGFP positive (transfected) and EGFP negative (non-transfected) fractions. B). Androgen receptor (AR) level was analyzed by Western Blot to verify the purity of each fraction after cell sorting. C). Immunofluorescence analysis of N-cadherin (red fluorescence) expression in LNCaP cells transfected with EGFP-tagged (green fluorescence) AR-WT, AR Q640X or AR Q670X expression plasmid. Magnification: ×20. doi:10.1371/journal.pone.0063466.g002
In this study, we have shown that N-cadherin is upregulated in LNCaP cells expressing constitutively active AR variants, but not in LNCaP cells overexpressing a full-length AR. These data suggest for the first time that constitutively active AR variants can induce N-cadherin expression. This finding should be connected to recent studies reporting a correlation between CRPC and N-cadherin upregulation [22, 23, 24]. Consistent with these studies, our data suggest that constitutively active AR variants signaling could be a mechanism leading to N-cadherin expression in CRPC.

These findings again highlight the link between AR signaling pathway and N-cadherin expression. Recent studies suggest that AR negatively regulates N-cadherin expression [22, 23]. Indeed, N-cadherin upregulation is associated with a decreased expression of AR in castration-resistant PCa xenografts [23]. Furthermore, the upregulation of N-cadherin observed in the castration-resistant LNCaP-19 cells can be reversed in the presence of androgens [22, 26, 27]. In accordance with these data, we have shown that androgens were associated with a decreased N-cadherin expression in our model overexpressing a constitutively active androgen receptor variant. These results suggest that AR-FL and constitutively active AR variants could act differently (Figure 3C). For example, DHT-stimulated AR-FL might recruit co-repressors and, in turn, represses N-CADHERIN expression. Besides, constitutively active AR variants lacking of carboxy-terminal region might behave differently and induce N-CADHERIN expression. Furthermore, AR-FL and constitutively active AR variants could compete with each other for regulating N-cadherin expression. Consistent with this hypothesis, N-CADHERIN gene contains a cluster of androgen response elements (ARE) repeats in intron 1 [28]. However, constitutively active AR variants could also indirectly control N-CADHERIN expression. For example, in prostate cancer, N-CADHERIN expression was associated with a nuclear translocation of Twist1 [29]. Although our data showed no significant difference in TWIST1 mRNA levels, constitutively active AR variants might enhance nuclear translocation of Twist1, which could in turn induce N-CADHERIN expression after binding to the E-box within the first intron of N-CADHERIN.
These hypotheses deserve to be studied in further studies to understand how constitutively active AR variants regulate N-CADHERIN expression.

In this study, we have also shown that constitutively active AR variants were associated with an increased expression of mesenchymal markers as VIMENTIN, SNAIL and ZEB1. These results are consistent with a recent study, which showed an increase of mesenchymal markers in tumors from patients treated with androgen deprivation therapy [24]. Taken together, our findings suggest that constitutively active AR variants could be associated with EMT process. However, these markers are not consistently associated with EMT. For example, SNAIL confers resistance to apoptosis to tumor cells exposed to ionizing radiations and genotoxic drugs, and enables breast cells to become tumor-initiating cells [30,31,32,33,34].

The expression of mesenchymal markers reported here in the presence of constitutively active AR variants was not associated with a downregulation of E-cadherin in our model. The inverse correlation between N-cadherin upregulation and E-cadherin downregulation is still debated. Indeed, McKeithen and colleagues, and more recently Tiwari and colleagues report a co-expression of both E- and N-cadherins in tumor cells [35,36]. In these studies E-cadherin protein displays a different subcellular localization. Moreover, the reported N-cadherin upregulation after castration in LNCaP-19 cells is not accompanied by a decrease of E-cadherin expression in vitro cell culture [22]. Nevertheless, the expected E-cadherin downregulation in this model is only observed in orthotopic tumors after castration, but not in subcutaneous LNCaP-19 tumors, suggesting an important role of the surrounding prostatic environment for E-cadherin downregulation [22]. Besides, an inverse correlation between castration-induced N-cadherin expression and E-cadherin down-regulation has been documented in LAPC9 and LaCaP35 subcutaneous xenografts models [23,24]. However, this cadherins switch has not been reported in two studies focusing on human clinical prostate tumors, from patients with or without androgen deprivation therapy [22,24].

Further studies are warranted to understand functional consequences of N-cadherin and other mesenchymal markers upregulation in the presence of constitutively active AR variants. N-cadherin expression is widely associated with tumor progression not only to its role in migration and invasion. Indeed, N-cadherin favors the migration of cancer cells via cytoskeleton reorganization and lamellipodia formation [14]. It also promotes the migration of cancer cells establishing homophilic interactions with neighboring tissues such as the stromal tissue or endothelium [37,38]. N-cadherin expression is also associated with survival in prostate cancer cells and melanoma cells. Indeed, N-cadherin expression can activate the phosphatidylinositol 3-kinase (PI3K)/AKT pathway to inactivate pro-apoptotic proteins and to induce an increase of anti-apoptotic proteins as Bcl-2 [39,40]. Finally, a recent study showed that N-cadherin could mediate angiogenesis by inducing monocyte chemoattractant protein-1 (MCP-1) expression via the PI3K/AKT pathway [41].

There is presently great interest in the mode of action of constitutively active AR variants in CRPC. In this study, we have shown for the first time that constitutively active AR variants induce N-cadherin expression and other mesenchymal markers in PCa. These findings support the hypothesis that these constitutively active AR variants could contribute to systemic dissemination of PCa cells, and reinforce the importance to target these AR variants in PCa.

Figure 4. Upregulation of mesenchymal markers by constitutively active androgen variants in prostate cancer cells. LNCaP cells were transfected with the ARWT, ARQ640X or AR-V7 expression plasmid or the empty plasmid (C3). A). E-CADHERIN, B). VIMENTIN, C). TWIST1, D). SNAIL and E). ZEB1 expression levels were analyzed by qRT-PCR at day-9 after transfection. For each sample, expression levels were normalized to PBGD or β-ACTIN and reported as relative value to LNCaP parental cell line. Values are presented as the mean of ΔACt ± SEM. NS: Not Significant * P<0.05, **P<0.01 and ***P<0.001. F). Western Blot showing evolution of ZEB1 expression in LNCaP cells overexpressing constitutively active AR variants. Immunoblot from 100 μg of total protein extracts. β-actin was used as loading control.
doi:10.1371/journal.pone.0063466.g004
Supporting Information

Figure S1 N-cadherin expression was upregulated in C4-2B cells in the presence of constitutively active AR variants. N-cadherin expression was assessed by qRT-PCR in C4-2B cells overexpressing AR Q640X variant or transfected with empty plasmid (C3) 4 days after transfection. Parental C4-2B cells were used as control. N-CADHERIN expression was normalized to β-ACTIN and calculated using the ΔΔCt method. Results are presented as the mean of ΔΔCt ± SEM from three independent experiments. NS: Not Significant * P<0.05, **P<0.01 and ***P<0.001.

Figure S2 DHT activated AR-FL repressed N-cadherin expression induced by constitutively active AR variants. 22Rv1 cells were cultured in complete medium supplemented with 100 nM and 1 μM of MDV3100 or DMSO. N-cadherin expression was normalized to DD Ct 6 method. Results are 0.05, **P<0.01 and ***P<0.001. Analyzed the data: FC JC. Contributed technical assistance for cell sorting, and Pr. Etienne Weiss (ESBS, Illkirch, France) for cell imaging.

References

1. Cunha GR, Rieke W, Thomson A, Marker PC, Rishrieger G, et al. (2004) Hormonal, cellular, and molecular regulation of normal and neoplastic prostatic development. J Steroid Biochem Mol Biol 92: 221–236.
2. Ceraline J, Cruchant MD, Erdmann E, Erbs P, Kurtz JE, et al. (2004) Constitutive activation of the androgen receptor by a point mutation in the hinge region: a new mechanism for androgen-independent growth in prostate cancer. Int J Cancer 108: 152–157.
3. Lapouge G, Erdmann E, Marcias G, Jagla M, Monge A, et al. (2007) Unexpected paracrine action of prostate cancer cells harboring a new class of androgen receptor mutation—a new paradigm for cooperation among prostate tumor cells. Int J Cancer 121: 1238–1244.
4. Marcias G, Erdmann E, Lapouge G, Siebert C, Barthelmey P, et al. (2010) Identification of novel truncated androgen receptor (AR) mutants including unreported pre-mRNA splicing variants in the 22Rv1 hormone-refractory prostate cancer (PCa) cell line. Hum Mutat 31: 74–80.
5. Bergerat JP, Ceraline J (2009) Pleiotropic functional properties of androgen receptor mutants in prostate cancer. Hum Mutat 30: 145–157.
6. Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ (2008) Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 68: 5469–5477.
7. Guo Z, Yang X, Sun F, Jiang R, Linn DE, et al. (2009) A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen-depletion-resistant growth. Cancer Res 69: 2305–2313.
8. Hornberg E, Ytialo EB, Cnolaic S, Atni H, Siutin P, et al. (2011) Expression of Androgen Receptor Splice Variants in Prostate Cancer Bone Metastases is Associated with Castration-Resistance and Short Survival. PLoS One 6: e19059.
9. Hu K, Dunn TA, Wei S, Isharwal S, Veltri RW, et al. (2009) Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 69: 14–22.
10. Watowson PA, Chen YF, Balbas MD, Wongsawat J, Socci ND, et al. (2010) Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci U S A 107: 16757–16765.
11. Li Y, Chan SC, Brand LJ, Hwang TH, Silverstein KA, et al. (2013) Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res 73: 403–409.
12. Mostaghel EA, Marv KF, Pymate SR, Vesalaa RL, Balk S, et al. (2011) Resistance to CYP1A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res 17: 5913–5925.
13. Lapouge G, Marcias G, Erdmann E, Rosler P, Cruchant M, et al. (2008) Specific properties of a C-terminal truncated androgen receptor detected in tumor cells. Int J Dev Biol 48: 463–476.
14. Derycke LD, Bracke ME (2004) N-cadherin in the spotlight of cell-cell adhesion, differentiation, embryogenesis, invasion and signalling. Int J Dev Biol 48: 463–476.
15. Gumbiner BM (2005) Regulation of cadherin-mediated adhesion in morphogenesis. Nat Rev Mol Cell Biol 6: 622–634.
16. Kalilf R (2009) EMT: when epithelial cells decide to become mesenchymal-like cells. J Clin Invest 119: 1417–1419.
17. Polyn K, Weinberg RA (2009) Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 9: 265–273.
18. Vuogari A, Pintzas A (2009) Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim Biophys Acta 1796: 75–90.
19. Tomita K, van Bokhoven A, van Leenders GJ, Ruiter ET, Jansen CF, et al. (2009) Cadherin switching in human prostate cancer progression. Cancer Res 69: 5469–5476.
20. Clarke NW, Hart CA, Brown MD (2009) Molecular mechanisms of metastasis in prostate cancer. Asian J Androl 11: 57–67.
21. Jin JK, Dayani F, Gallick GE (2011) Steps in prostate cancer progression that lead to bone metastasis. Int J Cancer 128: 2545–2561.
22. Jeubbacken K, Tsen T, Wang W, Gustavsson H, Damber JE, et al. (2010) N-cadherin increases after androgen deprivation and is associated with metastasis in prostate cancer. Endocr Relat Cancer 17: 469–479.
23. Takano H, Kono E, Tran C, Miyazaki H, Yamashiro J, et al. (2010) Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance. Nat Med 16: 1414–1420.
24. Sun Y, Wang BE, Leong KG, Yue P, Li L, et al. (2012) Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy. Cancer Res 72: 527–536.
25. Goyader C, Ceraline J, Gravier E, Morin A, Michel S, et al. (2012) Risk of hormone escape in a human prostate cancer model depends on therapy modalities and can be reduced by tyrosine kinase inhibitors. PLoS One 7: e2535.
26. Gustavsson H, Welen K, Damber JE (2005) Transition of an androgen-dependent human prostate cancer cell line into an androgen-independent subline is associated with increased angiogenesis. Prostate 62: 364–373.
27. Jeubbacken K, Gustavsson H, Welen K, Vallbo G, Damber JE (2006) Prostate cancer progression into androgen independence is associated with alterations in cell adhesion and invasion. Prostate 66: 1631–1640.
28. Takayama K, Kaneshiro K, Tsutsumi S, Horie-Inoe K, Ikeda K, et al. (2007) Identification of novel androgen response genes in prostate cancer cells by coupling chromatin immunoprecipitation and genomic microarray analysis. Oncogene 26: 4453–4463.
29. Alexander NR, Tran NL, Rekapalli H, Summers CE, Glackin C, et al. (2006) N-cadherin gene expression in prostate carcinoma is modulated by integrin-dependent nuclear translocation of Twist. Cancer Res 66: 3363–3369.
30. de Herreros AG, Peiro S, Sassour M, Savagur P (2010) Snai family regulation and epithelial mesenchymal transitions in breast cancer progression. J Mammary Gland Biol Neoplasia 15: 135–147.
31. Ercival M, Peiro S, Herranz N, Villagrasa P, Dave N, et al. (2000) Repression of NPTEN phosphatase by Snail1 transcriptional factor during gamma radiation-induced apoptosis. Mol Cell Biol 28: 1529–1540.
32. Kajita M, McClintic KN, Wade PA (2004) Abrerrant expression of the transcription factors snail and slug alters the response to genotoxic stress. Mol Cell Biol 24: 7539–7556.
33. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, et al. (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133: 704–715.
34. Morel AP, Lievre M, Thomas C, Hinkel G, Auneau S, et al. (2008) Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One 3: e2888.
35. McKeithen D, Graham T, Chung LW, Odero-Marah V (2010) Snail transcription factor regulates neurenomed differentiation in LNCaP prostate cancer cells. J Clin Invest 119: 1417–1419.
36. Sitwani N, Meyer-Schaller A, Arnold P, Antoniades P, Paciosow M, et al. (2013) KISS Is a Transcriptional Regulator of Genes Critical for EMT, Including Jnk1 [Mapk7]. PLoS One 8: e57329.
37. Bera G, van Roy F (2009) Involvement of members of the cadherin superfAMILY in cancer. Cold Spring Harb Perspect Biol 1: a003129.
38. Hazan RB, Phillips GR, Qiao RF, Norton L, Aaronson SA (2000) Exogenous expression of N-cadherin in breast cancer cells induces cell migration, invasion, and metastasis. J Cell Biol 148: 779–790.

39. Li G, Satyamoorthy K, Herlyn M (2001) N-cadherin-mediated intercellular interactions promote survival and migration of melanoma cells. Cancer Res 61: 3819–3825.

40. Tran NL, Adams DG, Vaillancourt RR, Heimark RL (2002) Signal transduction from N-cadherin increases Bcl-2. Regulation of the phosphatidylinositol 3-kinase/Akt pathway by homophilic adhesion and actin cytoskeletal organization. J Biol Chem 277: 32905–32914.

41. Nalla AK, Estes N, Patel J, Rao JS (2011) N-cadherin mediates angiogenesis by regulating monocyte chemoattractant protein-1 expression via PI3K/Akt signaling in prostate cancer cells. Exp Cell Res 317: 2512–2521.